We checked this claim: is it true that
clinical evidence across major late-stage biotechnology trials in early October 2026 was mixed rather than uniformly positive?
Vaxcyte posted positive late-stage pneumonia vaccine data while Argenx scrapped its Phase 3 Sjögren's study for futility
Argenx halts major drug trial as sector splits
Shares tumble as a key autoimmune study folds while vaccine rival Vaxcyte surges.
In a nutshell
Biotechnology investors were reminded of clinical trial risk in early October 2026 when two major late-stage programs produced opposite outcomes within days. Vaxcyte shares jumped after its pneumonia vaccine candidate reported strong trial findings, validating its commercial position in adult immunization. But broader sector optimism stalled three days later when Argenx aborted a Phase 3 study of its antibody therapy Vyvgart in Sjögren's disease after independent monitors found it ineffective, driving its stock down and underscoring the hazards of expanding approved medicines into new chronic diseases.
Highlights
- Vaxcyte shares surged on October 5 following positive trial data for its adult pneumonia vaccine candidate.
- Argenx terminated its Phase 3 UNITY trial on October 8 after an interim review found the drug ineffective in Sjögren's disease.
- Independent monitoring committee data showed efgartigimod was unlikely to meet the trial's main goal.
- Argenx shares dropped sharply following the study cancellation, tempering earlier sector optimism.
- As of October 12, Argenx has focused on other indications while Vaxcyte moves toward regulatory talks.
From the Editor’s Diary
Late-stage drug trials reward focused biological targets but offer no guarantees, proving that success in one chronic disease cannot be assumed to carry over into another.
Who's involved
Vaxcyte
U.S. biotechnology company developing vaccines
goal → secure regulatory clearance and market share for its experimental pneumonia shot
Argenx
Dutch-Belgian biotechnology company specializing in antibody therapies
goal → expand its flagship medicine Vyvgart into Sjögren's disease and other indications
Independent Data Monitoring Committee
clinical trial safety and efficacy oversight panel
goal → review interim UNITY study results for patient safety and therapeutic benefit
In short
Late-stage drug trials diverged sharply in early October 2026, showing that clinical progress in the biotechnology sector remains volatile rather than broadly assured. The split matters because it demonstrates that proven blockbuster medicines cannot easily expand into new chronic conditions even as novel preventive shots advance.
The most likely immediate outcome is that drugmakers will face tighter investor scrutiny over label expansions while preventive pipeline programs advance toward regulators.
This outcome is likely because the contrasting results directly altered commercial prospects and shifted capital toward validated late-stage programs while penalizing speculative expansion efforts.
Flagged by: Life & Health Science Barometer · 11 October 2026
How it unfolded
Vaxcyte advances pneumonia candidate on strong study data
The investigation opened with a positive clinical signal in preventive medicine when Vaxcyte demonstrated that its experimental pneumonia vaccine met key late-stage goals, confirming that new immunization approaches can succeed in mature commercial markets.
Argenx trial failure checks biotechnology momentum
Just three days after Vaxcyte's advance, the sector met an abrupt obstacle when Argenx disclosed that its Phase 3 UNITY trial had failed an interim review, making a broader industry rally unlikely. Independent monitors determined that the company's medicine, efgartigimod, offered no meaningful benefit for adults with primary Sjögren's disease, an autoimmune condition that causes chronic dry eyes and mouth. Argenx halted the study immediately, wiping out expectations for the new use and sending its shares tumbling.
Where things stand
As of October 12, 2026, the clinical split stands without reversal. Argenx has redirected its resources toward other approved and experimental autoimmune uses for efgartigimod, while Vaxcyte prepares for regulatory discussions to advance its pneumonia shot toward commercial approval.